Kantar Health Blog

  • Stephanie Hawthorne
    Oncology Conference Insight: ECC 2013 --- In recent years, angiogenesis inhibition, and VEGFR inhibition in particular, has been the most promising therapeutic target in advanced ovarian cancer, and the VEGF-targeted monoclonal antibody Avastin® (bevacizumab, Roche/Genentech) has been the major player in drug development for this tumor type. With Phase III trials conducted in multiple settings in ovarian cancer, Avastin has demonstrated a progression-free survival (PFS) benefit in first-line, recurrent platinum-sensitive, and recurrent platinum-resistant patients, and in the past two years, it has received regulatory approval in the European Union for use in the first-line/maintenance and recurrent platinum-sensitive settings.
    Continue Reading > | Go comment! | Share
  • The Next Showdown in BRAF-Mutant Melanoma

    by Stephanie Hawthorne | Sep 30, 2013
    Stephanie Hawthorne
    Oncology Conference Insight: ECC 2013 --- The melanoma field exploded two years ago, with the 2011 and 2012 approvals of Yervoy® (ipilimumab, Bristol-Myers Squibb) and Zelboraf® (vemurafenib, Genentech/Roche/Daiichi Sankyo). The approval of Zelboraf also ushered in the era of personalized medicine in melanoma, effectively segmenting the market in half – those patients with BRAF V600E mutation (approximately 44% of patients), and those without. In May 2013, the field expanded again following the FDA approvals of Tafinlar® (dabrafenib, GlaxoSmithKline) and Mekinist® (trametinib, GlaxoSmithKline), and one month later the European Medicines Agency (EMA) approval of Tafinlar, for treatment of BRAF-mutant unresectable or metastatic melanoma.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ECC 2013 --- Two late-breaking abstracts during the colorectal cancer sessions at the 2013 European Cancer Congress were centered on the anti-EGFR therapies Erbitux® (cetuximab, Bristol-Myers Squibb/Eli Lilly/Merck KGaA) and Vectibix® (panitumumab, Amgen/Takeda). Although the data probably won’t immediately change clinical practice, questions continue to arise. If answered favorably, these therapies could conceivably be utilized more strongly in KRAS wild-type patients.
    Continue Reading > | Go comment! | Share
  • Neesha Suvarna
    Oncology Conference Insight: ASCO 2013 --- Chronic lymphocytic leukemia (CLL) is a disease of the elderly, with a median age of diagnosis at 71 in the United States and nearly 40% of patients are older than 75 at the time of diagnosis. Standard treatment for “fit” patients is aggressive chemotherapy, but existing co-morbidities in elderly patients often precludes the use of these highly toxic regimens.
    Continue Reading > | Go comment! | Share
  • Neesha Suvarna
    Oncology Conference Insight: ASCO 2013 --- Anaplastic lymphoma kinase (ALK) was originally discovered as a fusion oncogene with nucleophosmin (NPM) in a subset of anaplastic large cell lymphomas (ALCL). When fused to other proteins, ALK becomes constitutively active, leading to increased catalytic kinase activity and oncogenic function.
    Continue Reading > | 2 Comments | Share